Sarcoma and other solid tumors

UCSF Protocol No. ClinicalTrials.gov Protocol No. PI Name Title  
 Pediatric Cancers > Germ Cell Tumors  
AGCT1531 NCT03067181 Rangaswami, Arun A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors  
AGCT1532 NCT02582697 Rangaswami, Arun A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors  
ALLIANCE-A031102 NCT02375204 Rangaswami, Arun A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors  
 Pediatric Cancers > Liver Tumors > New Diagnosis  
AHEP1531 NCT03533582 Rangaswami, Arun Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)  
 Pediatric Cancers > Liver Tumors > Relapsed/Refractory Pediatric Tumors  
20081 NCT04134559 Rangaswami, Arun The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates. A Phase II Study  
 Pediatric Cancers > Phase 1 Clinical Trials  
16081 NCT02650401 Sabnis, Amit A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF ENTRECTINIB (RXDX-101) IN PEDIATRICS WITH LOCALLY ADVANCED OR METASTATIC SOLID OR PRIMARY CNS TUMORS AND/OR WHO HAVE NO SATISFACTORY TREATMENT OPTIONS  
19082 NCT03654716 Vo, Kieuhoa Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer  
Pediatric Cancers > Rare Tumors  
14083 NCT02124772 Mueller, Sabine An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations  
ADVL1622 NCT02867592 Vo, Kieuhoa Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors  
ADVL1823 NCT03834961 Vo, Kieuhoa Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias  
 Pediatric Cancers > Relapsed/Refractory Pediatric Tumors   
150816 NCT02601937 Vo, Kieuhoa A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma  
160825 NCT03690869 Mueller, Sabine A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma  
160829 NCT02909777 Vo, Kieuhoa Phase 1 Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma  
ADVL1312 NCT02095132 Vo, Kieuhoa A Phase 1/2 Study of AZD1775 (MK-1775) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors  
ADVL1414 NCT02323880 Vo, Kieuhoa  A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors  
ADVL1514 NCT02975882 Vo, Kieuhoa A Phase 1 Study of ABI-009 (nab-Rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan  
ADVL1614 NCT03320330 Vo, Kieuhoa A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors  
ADVL1615 NCT03323034 Vo, Kieuhoa A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors  
ADVL1711 NCT03245151 Vo, Kieuhoa A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  
ADVL1921 NCT03709680 Vo, Kieuhoa PHASE 1 STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS  
APEC1621A NCT03213704 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions  
APEC1621B NCT03210714 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493  (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations  
APEC1621C NCT03213665 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients with Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex  
APEC1621D NCT03213678 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of Ly3023414 in Patients with Solid Tumors  
APEC1621E    NCT03213691 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations  
APEC1621F NCT03213652 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Ensartinib in Patients with Tumors Harboring ALK or ROS1 Genomic Alterations  
APEC1621G NCT03220035 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations  
APEC1621H NCT03233204 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes  
APEC1621I NCT03526250 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes  
APEC1621J NCT03698994 Rangaswami, Arun NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations  
APEC1621SC NCT03155620 Rangaswami, Arun

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

   
ARST1921 NCT04195399 Rangaswami, Arun A Safety, Pharmacokinetic and Efficacy Study of a Y-Secretase Inhibitor, Nirogacestat (PF-03084014) in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors  
Pediatric Cancers > Soft Tissue Sarcomas  
150814 NCT02520713 Sabnis, Amit Multicenter Cohort Study To Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Solid Tumors: The iCat2, GAIN Consortium Study  
ARST1431 NCT02567435 Rangaswami, Arun A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) versus VAC/VI plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)